Naloxone in treating central adverse effects during opioid titration for cancer pain.
Mercadante
Sebastiano
S
Villari
Patrizia
P
Ferrera
Patrizia
P
D000368:Aged; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000506:poisoning* / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D064420:Drug-Related Side Effects and Adverse Reactions / Q000188:drug therapy*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000150:complications*; D008297:Male; D009020:Morphine / Q000008:administration & dosage / Q000506:poisoning* / Q000627:therapeutic use*; D009270:Naloxone / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000627:therapeutic use*; D010146:Pain / Q000188:drug therapy* / Q000209:etiology*
D000701:Analgesics, Opioid; D009292:Narcotic Antagonists; D009270:Naloxone; D009020:Morphine